Cargando…

Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI‐110) in Myeloid Malignancies

Guadecitabine (SGI‐110) is a novel next‐generation hypomethylating agent (HMA) administered as s.c. injection with extended decitabine exposure. Dose/exposure‐response analyses of longitudinal measures of long interspersed nucleotide element‐1 (LINE‐1) methylation and absolute neutrophil counts (ANC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Cong, Goggin, Timothy K., Su, Xiang‐Yao, Taverna, Pietro, Oganesian, Aram, Lowder, James N., Azab, Mohammad, Kantarjian, Hagop
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658282/ https://www.ncbi.nlm.nih.gov/pubmed/28960845 http://dx.doi.org/10.1002/psp4.12248

Ejemplares similares

Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma
por: Jueliger, Simone, et al.
Publicado: (2016)

Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma
por: Wong, Jonathan, et al.
Publicado: (2022)

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
por: Papadatos-Pastos, Dionysis, et al.
Publicado: (2022)

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia
por: Roboz, Gail J., et al.
Publicado: (2017)

Immunomodulatory activity of SGI-110: a basis for novel chemo-immunotherapeutic combinations in cancer treatment
por: Covre, Alessia, et al.
Publicado: (2013)

Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia
por: Chung, Woonbok, et al.
Publicado: (2019)

Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts
por: Srivastava, Pragya, et al.
Publicado: (2015)

Mass balance and metabolite profiling of (14)C-guadecitabine in patients with advanced cancer
por: Roosendaal, Jeroen, et al.
Publicado: (2019)

Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study
por: Fenaux, Pierre, et al.
Publicado: (2023)

SPIRE – combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial
por: Crabb, Simon, et al.
Publicado: (2018)

DNA methylation subtypes guiding prognostic assessment and linking to responses the DNA methyltransferase inhibitor SGI-110 in urothelial carcinoma
por: Li, Juan, et al.
Publicado: (2022)

Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine
por: Albany, Costantine, et al.
Publicado: (2016)

Two New SGI1-LK Variants Found in Proteus mirabilis and Evolution of the SGI1-HKL Group of Salmonella Genomic Islands
por: de Curraize, Claire, et al.
Publicado: (2020)

3rd European Cray/SGI MPP Workshop
Publicado: (1997)

5th European SGI-Cray MPP Workshop
Publicado: (1999)

SGI: automatic clinical subgroup identification in omics datasets
por: Buyukozkan, Mustafa, et al.
Publicado: (2021)

Molecular mechanisms of Guadecitabine induced FGFR4 down regulation in alveolar rhabdomyosarcomas
por: Darvishi, Emad, et al.
Publicado: (2020)

Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy
por: Kadia, Tapan Mahendra, et al.
Publicado: (2019)

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
por: Jabbour, Elias, et al.
Publicado: (2010)

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
por: Hochhaus, Andreas, et al.
Publicado: (2013)

Suboptimal Responses in Chronic Myeloid Leukemia
por: Jabbour, Elias, et al.
Publicado: (2012)

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
por: Sébert, Marie, et al.
Publicado: (2019)

Development and targeted use of nilotinib in chronic myeloid leukemia
por: Fava, Carmen, et al.
Publicado: (2009)

Erratum for de Curraize et al., “Two New SGI1-LK Variants Found in Proteus mirabilis and Evolution of the SGI1-HKL Group of Salmonella Genomic Islands”
por: de Curraize, Claire, et al.
Publicado: (2020)

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia
por: Bidikian, Aram, et al.
Publicado: (2022)

A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer
por: Albany, Costantine, et al.
Publicado: (2020)

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
por: Short, Nicholas J., et al.
Publicado: (2019)

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia
por: Briski, Robert, et al.
Publicado: (2023)

DNA Methyltransferase 1 Targeting Using Guadecitabine Inhibits Prostate Cancer Growth by an Apoptosis-Independent Pathway
por: Karan, Dev, et al.
Publicado: (2023)

Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells
por: Amaro, Adriana, et al.
Publicado: (2023)

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
por: George, Binsah, et al.
Publicado: (2021)

“Does the Salmonella Genomic Island 1 (SGI1) confer invasiveness properties to human isolates?”
por: de Curraize, Claire, et al.
Publicado: (2017)

DNMTs inhibitor SGI-1027 induces apoptosis in Huh7 human hepatocellular carcinoma cells
por: Sun, Ning, et al.
Publicado: (2018)

Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study
por: Wang, Xiaoning, et al.
Publicado: (2013)

Identification and Characterization of New Resistance-Conferring SGI1s (Salmonella Genomic Island 1) in Proteus mirabilis
por: Bie, Luyao, et al.
Publicado: (2018)

SGI-4 in Monophasic Salmonella Typhimurium ST34 Is a Novel ICE That Enhances Resistance to Copper
por: Branchu, Priscilla, et al.
Publicado: (2019)

P672: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND T315I MUTATION AFTER FAILURE OF PRIOR THERAPIES
por: Bidikian, Aram, et al.
Publicado: (2023)

A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
por: Jang, H. Josh, et al.
Publicado: (2023)

Detection of SGI1/PGI1 Elements and Resistance to Extended-Spectrum Cephalosporins in Proteae of Animal Origin in France
por: Schultz, Eliette, et al.
Publicado: (2017)

Preclinical characterization of the JAK/STAT inhibitor SGI-1252 on skeletal muscle function, morphology, and satellite cell content
por: Sorensen, Jacob R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_udtlgs17itckrnegu43b8gdpu2